Pharmafile Logo
Pharmafocus logo
Advanced Search

rcc

Showing 15 posts of 19 posts found.

merckwindow_web

MSD announce new data from advanced renal cell carcinoma trial

June 8, 2021
Manufacturing and Production MSD, rcc

Merk (MSD) has announced positive data from its Phase III Clear/Keynote-581 trial on Keytruda (pembrolizumab) plus Lenvima (lenvatinib), and Lenvima …

News
FDA building

FDA approves AVEO’s kidney cancer treatment

March 11, 2021
Aveo, FDA, Kidney cancer, fotivda, rcc

The FDA has approved AVEO Oncology’s FOTIVDA drug for the treatment of adults with relapsed or refractory advanced renal cell …

News
merckwindow_web

MSD’s Keytruda combo therapy significantly improves survival in advanced renal cell carcinoma

February 18, 2019
Sales and Marketing Cancer, MSD, Merck Sutent, Pfizer, inlyta, keytruda, oncology, rcc, renal cell carcinoma

Merck & Co’s Keytruda (pembrolizumab) in combination with Pfizer’s Inlyta (axitinib) significantly extended the lives of those with advanced renal …

News

Scotland approves first-line treatment for advanced kidney cancer

July 9, 2018
Sales and Marketing Cancer, Scotland, fotivda, rcc, tivozanib

The Scottish Medicines Consortium has approved the use of EUSA Pharma’s Fotivda (tivozanib) as a first-line treatment for people with …

News
Pfizer image

SMC approves Inlyta

November 13, 2013
Sales and Marketing Pfizer, SMC, Sutent, inylta, rcc

Pfizer’s kidney cancer drug Inlyta has been approved by the drugs watchdog in Scotland, making it the only country in …

News
fda_sign_web

Double approval for Pfizer cancer drugs

September 6, 2012
Sales and Marketing CML, Cancer, Glivec, Pfizer, axitinib, rcc

 Two cancer drugs from Pfizer have been approved, one in Europe for kidney cancer and another in the US for …

News
Pfizer image

Torisel-Avastin combo fails in kidney cancer

August 13, 2012
Research and Development, Sales and Marketing R&D, Sutent, Torisel, avastin, failure, rcc

Combining Pfizer’s Torisel and Roche’s Avastin does not increase survival rates for advanced kidney cancer patients. This is according to …

News
Nexavar image

Torisel fails in head-to-head study with Nexavar

May 16, 2012
Research and Development, Sales and Marketing Bayer, Nexavar, Pfizer, Torisel, inlyta, rcc

Pfizer’s kidney cancer drug Torisel has failed to best Bayer’s Nexavar in a head-to-head trial.  The Phase III study was …

News

FDA approves Pfizer cancer drug Inlyta

January 30, 2012
Sales and Marketing Nexavar, Pfizer, Sutent, rcc, renal cell carcinoma

Pfizer’s kidney cancer drug Inlyta has gained US approval for second line treatment for the disease. Inlyta (axitinib) is now …

News
Pfizer HQ

Pfizer files new kidney cancer drug

June 2, 2011
Sales and Marketing Nexavar, Pfizer, rcc

Pfizer has filed its kidney cancer drug axitinib in the EU after impressive head-head- trials with Bayer’s Nexavar. Pfizer is …

News

Pfizer’s cancer drug meets end points in head-to-head study

May 20, 2011
Research and Development, Sales and Marketing Pfizer, axitinib, rcc

Pfizer’s investigational cancer drug axitinib significantly increased survival in kidney cancer patients when compared to Bayer’s standard treatment Nexavar. New …

News

Astellas to commercialise new kidney cancer drug in Europe

February 21, 2011
Sales and Marketing Astellas, Aveo Pharmaceuticals, Cancer, Kidney cancer, rcc, renal cell carcinoma, tivozanib

Astellas and Aveo Pharmaceuticals are to commercialise Aveo’s investigational kidney cancer drug tivozanib in Europe and the US. Aveo is …

News

GSK’s patient access scheme for Votrient sways NICE

December 24, 2010
Sales and Marketing GSK, GlaxoSmithKline, NICE, Votrient, pazopanib, rcc, renal cell carcinoma

NICE has recommended GlaxoSmithKline’s kidney cancer drug Votrient in final draft guidance after the pharma company offered to implement a …

News

The renal cell carcinoma market: Votrient to challenge Sutent’s lead

November 25, 2010
Sales and Marketing GSK, GlaxoSmithKline, Pfizer, Sutent, Votrient, rcc, renal cell carcinoma

After decades of no new medicines emerging to treat renal cell carcinoma, no fewer than five new drugs were approved …

Feature

GSK tipped to lead kidney cancer market

July 1, 2010
Sales and Marketing Kidney cancer, Patorma, Votrient, rcc

GlaxoSmithKline’s kidney cancer drug Votrient has been forecast as a future leader in a marketplace currently dominated by Pfizer. Analysts …

News

Latest content

GSK’s Jemperli approved in EU as treatment for endometrial cancer

December 11, 2023

Daiichi Sankyo shares results for Ezharmia as lymphoma treatment

December 11, 2023

Regeneron shares data for multiple myeloma treatment

December 8, 2023

Merck collaborates with Acceleration Consortium for AI experimentation

December 8, 2023

AbbVie to acquire Cerevel Therapeutics for approximately $8.7bn

December 7, 2023